Sentinel Node Biopsy in Early Breast Cancer

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Breast cancer (BC) treatment is evolving due to a better understanding of BC biology.
• Axillary staging is critical for early-stage BC outcomes.
• Sentinel lymph node biopsy (SLNB) is a key technique for axillary staging.

Purpose of the Study:

• To evaluate the role and impact of SLNB in managing the axilla in breast cancer patients.
• To compare outcomes between SLNB and axillary node dissection (ALND).
• To determine criteria for omitting ALND in early breast cancer.

Main Methods:

• Review of clinical trials and evidence regarding SLNB and ALND.
• Analysis of surgical morbidity, local recurrence, and survival rates.
• Assessment of the impact of micrometastasis detection on patient outcomes.

Main Results:

• SLNB accurately stages the axilla, with no significant difference in survival or local recurrence compared to ALND after a negative SLNB.
• SLNB significantly reduces surgical morbidity, including lymphedema and neuropathy, and improves quality of life.
• ALND can be omitted in specific patient groups (e.g., ≥2 positive nodes with conservative treatment), while still recommended in others (e.g., clinically N1 BCs, ≥3 positive nodes).
• Micrometastasis detection via immunohistochemistry does not affect disease-free or overall survival.

Conclusions:

• SLNB has revolutionized early breast cancer surgical treatment by reducing morbidity without compromising survival.
• A tailored approach to axillary management, considering tumor biology over nodal status alone, is recommended.
• SLNB alone is sufficient for managing micrometastatic disease.